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EDITORIAL
An  Integrated  therapeutic  approach:  do COPD  comorbidities
justify it?
Uma  abordagem  terapêutica  integrada:  as  comorbilidades  na  DPOCb
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Chronic  obstructive  pulmonary  disease  (COPD)  remains  a
major  public  health  problem,  causing  considerable  morbid-
ity  and  mortality;  it  has  risen  from  the  fourth  most  common
cause  of  death  in  1990  to  the  third  from  2010.1 This  dark
prognostication  is  consistent  with  US  data  showing  a  progres-
sive  age-speciﬁc  rise  in  mortality  from  COPD  in  both  males
and  females  over  the  last  50  years.2
Previous  studies  in  Portugal  have  also  identiﬁed  an
increase  in  the  prevalence  of  COPD  from  5.3%  in  20023 to
14.2%  in  2013,4 although  they  were  measured  by  somewhat
different  methods,5 and  the  number  of  deaths  in  the  coun-
try  accounts  for  up  to  2,743  COPD  patients  per  year.6 The
same  source6 states  that  800  000  Portuguese  people  suf-
fer  from  COPD  nowadays,  yet  more  than  660,000  are  still
undiagnosed.5
It  is  increasingly  recognised  that  COPD  often  coexists
with  other  chronic  diseases  and  that  these  comorbidi-
ties  contribute  to  patient  health  status  and  prognosis.7,8
Comorbidities  and  also  exacerbations  were  introduced  into
the  COPD  deﬁnition  in  the  second  GOLD  revision7 as  they
have  a  role  in  the  severity  of  the  disease  in  individual
patients.  Extrapulmonary  manifestations  of  COPD  are  typ-
ically  believed  to  be  linked  to  progression  of  the  disease;
examples  such  as  skeletal  dysfunction,  lean  mass  depletion,
and  osteoporosis  and  osteopenia.9,10 In  other  comorbidities
such  as  cardiovascular  diseases  (CVD),  systemic  inﬂamma-
tion  has  been  proposed  as  an  explanation  for  the  association
between  them  and  COPD.11 In  fact,  epidemiological  data
suggest  that  COPD  patients  are  at  a  greater  risk  of  CVD
compared  with  age-  and  sex-  matched  controls.12
Autonomic  imbalance,  vascular  endothelial  dysfunction
and  lower  arterial  compliance  may  be  implicated  in  this
association.11 Also  the  decreased  physical  activity  observed
in  all  severity  stages  of  COPD  patients13 may  increase  CVD
and  other  comorbidities  risks.
Furthermore,  pulmonary  neoplasms,  anxiety  and  depres-
sion  are  highly  prevalent  in  COPD  patients7,8,  the  former
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moke,  and  the  latter  because  of  social  isolation  and  physi-
al  impairment.
A  recent  study14 showed  that  comorbidities  are  predom-
nantly  present  in  ‘‘symptomatic’’  GOLD  groups  B  and  D.
The  presence  of  comorbidities  in  these  patients  certainly
equires  proper  diagnosis,  quantiﬁcation,  and  allocation  of
herapeutic  means.  It  is  interesting  that  all  COPD  multi
omponent  indices  until  very  recently  incorporated  many
omains  but  not  comorbidities.15 However,  two  new  indices,
OTE  and  CODEX  have  explicitly  incorporated  co  morbidities
s  added  dimensions  in  the  assessment  of  COPD  severity  and
rognosis16,17.
In  this  issue  of  the  Portuguese  Journal  of  Pulmonology,
reias  V  et  al18 report  on  the  distribution  of  comorbidi-
ies  in  patients  with  old  COPD  GOLD  4,  that  is  FEV1%
redicted  <  30%  and/or  chronic  respiratory  failure.  The
uthors  conclude  that  their  high  prevalence  justiﬁes  the
eed  for  a  comprehensive  and  integrated  therapeutic
pproach.
This  is  a  well  conducted  cross-sectional  study  with  a  ret-
ospective  analysis,  in  a well  deﬁned  patient  population,
ut  it  has  some  limitations:  The  absence  of  a  control  group
revented  the  authors  from  evaluating  the  effect  of  age
nd  gender  properly  as  well  as  other  factors  possibly  impli-
ated  in  the  prevalence  of  comorbidities;  the  limited  sample
ize  (n  =  89)  could  have  reduced  the  power  of  sub-analyses
nd  the  importance  of  the  results;  furthermore,  including
nly  GOLD  Stage  4  patients,  does  not  allow  for  generalizing
bout  the  prevalence  of  comorbidities  in  the  whole  COPD
opulation.
Nevertheless  the  results  are  important  and  similar  to
hose  reported  in  previous  studies19--21 in  relation  to  the
revalence  of  comorbidities  in  COPD  patients.The  increased  risk  of  lung  carcinoma  in  the  studied  pop-
lation  are  similar  to  that  described  by  other  authors15
nd  certainly  might  make  health  authorities  reconsider  the
gia.  Published  by  Elsevier  España,  S.L.  All  rights  reserved.
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mportance  and  utility  of  creating  a  lung  cancer  screening
rogram  in  COPD  patients.
The  ﬁnding  that  frequent  exacerbators  were  associated
ith  an  increased  risk  of  presenting  with  at  least  two
omorbidities  should  point  to  a  better  way  of  preventing
xacerbations  through  effective  management  of  comorbidi-
ies.
COPD  prevalence  in  Portugal  is  comparable  to  that  of
ome  European  countries  like  Germany  (13.2%)  and  Swe-
en  (16.2%),  which  implies  that  the  economic  investment
n  COPD  treatment  in  our  country  should  be  similar  to  that
n  those  countries  mentioned.
Projections  and  health  planning  regarding  COPD  are
ased  on  its  current  prevalence  together  with  demograph-
cs,  and  national  studies  aimed  at  determining  each  of  them
re  of  crucial  interest.  However,  a  holistic  estimate  of  the
urden  of  COPD  might  include  quantifying  comorbidities,
heir  severity,  and  therapy  requirements.  If  this  is  not  done,
he  burden  of  COPD  will  always  be  underestimated,  and  the
esources  allocated  to  disease  control  will  remain  insufﬁ-
ient.
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